ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 36900367

Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?

Gupta A and 2 others. Cancers (Basel), 2023. Cited by 26 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology? Papers, record 36900367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36900367

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?
PubMed
Journal
Cancers (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
2.29
iCite
Revised in PubMed
2024-09-27
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gupta AAmolhttps://orcid.org/0000-0001-8307-4192
2Kurzrock RRazelle
3Adashek JJJacob Jhttps://orcid.org/0000-0003-4272-312X

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
U10 CA180888NCI NIH HHSUnited StatesU10CA180888PubMed and NIHNIH RePORTER
UG1 CA233198NCI NIH HHSUnited StatesUG1CA233198PubMed and NIHNIH RePORTER
5U01CA180888-08HHSUnited StatesU01CA180888PubMedNIH RePORTER
5UG1CA233198-05HHSUnited StatesUG1CA233198PubMed and NIHNIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References123

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127,870,574
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
J Clin Oncol2017https://conductscience.org/library/papers/27870574PubMed
228,441,383The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.Br J Cancer2017https://conductscience.org/library/papers/28441383PubMed
332,416,072Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020https://conductscience.org/library/papers/32416072PubMed
425,744,437BRAF V600E mutation-specific antibody: A review.Semin Diagn Pathol2015https://conductscience.org/library/papers/25744437PubMed
523,251,089Dabrafenib and its potential for the treatment of metastatic melanoma.Drug Des Devel Ther2012https://conductscience.org/library/papers/23251089PubMed
627,095,655Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Nat Rev Gastroenterol Hepatol2016https://conductscience.org/library/papers/27095655PubMed
728,183,697Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).Cancer Discov2017https://conductscience.org/library/papers/28183697PubMed
822,356,324Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.N Engl J Med2012https://conductscience.org/library/papers/22356324PubMed
925,526,346Mutational landscape of intrahepatic cholangiocarcinoma.Nat Commun2014https://conductscience.org/library/papers/25526346PubMed
1030,031,797Molecular targeted therapy: Treating cancer with specificity.Eur J Pharmacol2018https://conductscience.org/library/papers/30031797PubMed

1 to 10 of 123

See all 123 references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
41,773,262Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps.Drug Des Devel Ther2026https://conductscience.org/library/papers/41773262PubMed
41,309,533Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Signal Transduct Target Ther2025https://conductscience.org/library/papers/41309533PubMed
40,870,997In Vitro and In Vivo Evaluation of Alectinib-Loaded Dendrimer Nanoparticles as a Drug Delivery System for Non-Small Cell Lung Carcinoma.Pharmaceutics2025https://conductscience.org/library/papers/40870997PubMed
40,281,353Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies.Int J Clin Oncol2025https://conductscience.org/library/papers/40281353PubMed
40,001,320A Comprehensive Analysis of FGF/FGFR Signaling Alteration in NSCLC: Implications in Prognosis and Microenvironment.Thorac Cancer2025https://conductscience.org/library/papers/40001320PubMed
38,672,619Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma.Cancers (Basel)2024https://conductscience.org/library/papers/38672619PubMed
38,645,422
Navigating uncharted territory: a case report and literature review on the remarkable response to personalized crizotinib containing combinational therapy in a pazopanib refractory patient with novel alterations.
Ther Adv Med Oncol2024https://conductscience.org/library/papers/38645422PubMed
38,612,518
ETV6::NTRK3 Fusion-Positive Wild-Type Gastrointestinal Stromal Tumor (GIST) with Abundant Lymphoid Infiltration (TILs and Tertiary Lymphoid Structures): A Report on a New Case with Therapeutic Implications and a Literature Review.
Int J Mol Sci2024https://conductscience.org/library/papers/38612518PubMed
37,894,467Don't Judge a Book by Its Cover: The Role of Statins in Liver Cancer.Cancers (Basel)2023https://conductscience.org/library/papers/37894467PubMed
37,834,032A Novel Mouse Model of Intrahepatic Cholangiocarcinoma Induced by Azoxymethane.Int J Mol Sci2023https://conductscience.org/library/papers/37834032PubMed

1 to 10 of 12

See all 12 cited by

Genes32

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
ATHS470PubTator's text mininghttps://conductscience.org/library/genes/470NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
BRCA1672PubTator's text mininghttps://conductscience.org/library/genes/672NCBI Gene
BRCA2675PubTator's text mininghttps://conductscience.org/library/genes/675NCBI Gene
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CTLA41,493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene

1 to 10 of 32

See all 32 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36900367

GET https://conductscience.org/api/papers/v1/36900367/references?page=2

API referenceFor AI assistants